Ergoteles’s Avalo Therapeutics AVTX Stock Holding History

Ergoteles’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-99	Closed	-$142K	–	1544
2022 Q2	$142K	Buy	+99	New	+$132K	﹤0.01%	1432
2021 Q4	–	Sell	-14	Closed	-$86K	–	1231
2021 Q3	$86K	Buy	+14	New	+$113K	﹤0.01%	1115

Other funds holding AVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ergoteles's AVTX Position: Q3 2022 in Review

Ergoteles sold out of Avalo Therapeutics (AVTX) in Q3 2022, closing a stake of 99 shares — an estimated $142K sold.

Ergoteles first reported a position in AVTX in Q3 2021 and held it in 2 quarters. The position peaked at $142K in Q2 2022. 18 funds tracked by Wall St. Rank hold AVTX as of Q3 2022.

Ergoteles reported no remaining Avalo Therapeutics position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 99 Avalo Therapeutics shares in Q3 2022, an estimated $142K.
Ergoteles first reported a position in Avalo Therapeutics in Q3 2021 and held it in 2 quarters.
Ergoteles's Avalo Therapeutics position peaked at $142K in Q2 2022.
18 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.